Plain-English translation of NCT05891145 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a medication called can help prevent a common complication after heart bypass surgery — an irregular heart rhythm called atrial fibrillation. About 30% of people who have bypass surgery develop this problem, even with current treatments. Researchers believe this newer sedative medication, which has anti-inflammatory properties, might reduce the risk.
Irregular heart rhythms after bypass surgery can cause serious complications and longer hospital stays. Current medications don't prevent this problem in all patients, so doctors are looking for new approaches — and this medication's ability to reduce inflammation makes it a promising candidate.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new sedative medication or a standard sedative during your bypass surgery. Before surgery, after surgery, and at follow-up visits, doctors would take blood samples to check for inflammation markers and heart injury signs, and they would monitor your heart rhythm. The study is designed in two phases: an initial pilot phase with 50 patients to gather information, followed by a larger double-blind study where neither you nor your doctors would know which medication you received.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
China